Research programme: monoclonal antibody therapeutics - Ganymed

Drug Profile

Research programme: monoclonal antibody therapeutics - Ganymed

Alternative Names: Anti-CLDN18.2 bispecific antibody - Ganymed Pharmaceuticals; Anti-CLDN18.2 drug conjugate - Ganymed Pharmaceuticals; Anti-CLDN6 bispecific antibody - Ganymed Pharmaceuticals; Anti-CLDN6 drug conjugate - Ganymed Pharmaceuticals

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Ganymed Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Claudin 18 protein inhibitors; Claudin 6 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Solid tumours

Most Recent Events

  • 21 Dec 2016 Ganymed Pharmaceuticals has been acquired by Astellas Pharma
  • 14 Feb 2014 Early research in Breast cancer and Solid tumours in Germany (Parenteral)
  • 04 Jun 2009 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top